



Title: Treosulfan, Fludarabine Conditioning for HSCT in Children with 
Primary Immunodeficiency: UK Experience 
 
Author: Mary A. Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh 
Nademi, Robert Chiesa, Reem Elfeky, Mark S. Pearce, Persis Amrolia, Austen 
Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, 
Hubert B. Gaspar, Andrew J. Cant, Andrew R. Gennery, Paul Veys 
 
PII:  S1083-8791(17)30825-X 
DOI:  https://doi.org/10.1016/j.bbmt.2017.11.009 
Reference: YBBMT 54865 
 
To appear in: Biology of Blood and Marrow Transplantation 
 
Received date: 5-9-2017 
Accepted date: 8-11-2017 
 
 
Please cite this article as:  Mary A. Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh 
Nademi, Robert Chiesa, Reem Elfeky, Mark S. Pearce, Persis Amrolia, Austen Worth, Terence 
Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, 
Andrew R. Gennery, Paul Veys, Treosulfan, Fludarabine Conditioning for HSCT in Children 
with Primary Immunodeficiency: UK Experience, Biology of Blood and Marrow Transplantation 
(2017), https://doi.org/10.1016/j.bbmt.2017.11.009. 
 
This is a PDF file of an unedited manuscript that has been accepted for publication.  As a service 
to our customers we are providing this early version of the manuscript.  The manuscript will 
undergo copyediting, typesetting, and review of the resulting proof before it is published in its 
final form.  Please note that during the production process errors may be discovered which could 





Treosulfan, fludarabine conditioning for HSCT in children with Primary Immunodeficiency: 1 
UK experience 2 
Authors 3 
Mary A.Slatter MD1, Kanchan Rao MD2, Intan Juliana Abd Hamid PhD1,3, Zohreh Nademi 4 
PhD1, Robert Chiesa MD2, Reem Elfeky MD2, Mark S. Pearce PhD4,  Persis Amrolia PhD2, 5 
Austen Worth PhD2, Terence Flood MD1, Mario Abinun MD1, Sophie Hambleton DPhil1, 6 
Waseem Qasim PhD2, Hubert B.Gaspar PhD2, Andrew J. Cant MD1, Andrew R. Gennery MD1, 7 
Paul Veys MD 8 
Institutions 9 
Department of Paediatric Immunology, Newcastle upon Tyne Hospital NHS Foundation 10 
Trust, Newcastle upon Tyne, UK1 11 
Great Ormond Street Hospital NHS Trust, London, UK2 12 
Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains 13 
Malaysia, Bertam Malaysia3  14 
Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK4 15 
Corresponding author 16 
Dr M.A. Slatter, 17 
Paediatric Immunology, Infectious Diseases & Allergy Department 18 
Clinical Resource Building, Block 2, Level 4 19 
Royal Victoria Infirmary, Queen Victoria Road,  20 
Newcastle upon Tyne, NE1 4LP, UK 21 
Page 1 of 38
2 
 
e-mail: mary.slatter@nuth.nhs.uk 22 
Phone: 0191 2823767   Fax: 0191 2820497 23 
There was no specific funding for this study. 24 
Conflict-of-interest disclosure: The authors declare no competing financial interests. 25 
 26 
27 




 Excellent outcome in children post HSCT with treosulfan, fludarabine, for PID. 29 
 Better myeloid chimerism with PBSC. No increased acute GVHD grade III/IV or 30 
chronic GVHD. 31 
 11 with SCID diagnosed at birth alive with up to 8.7 years follow up.  32 
 There was no veno- occlusive disease. 33 
 34 
 35 
Abstract  36 
We previously published results of 70 children who received treosulfan with 37 
cyclophosphamide (30) or fludarabine (40) before haematopoietic stem cell transplantation 38 
(HSCT) for Primary Immunodeficiency (PID). Toxicity was lower and T cell chimerism better in 39 
those receiving fludarabine, but numbers were relatively small and follow-up short. We now 40 
report outcome of 160 children who received homogeneous conditioning with treosulfan, 41 
fludarabine mostly with alemtuzumab (n=124). 42 
Median age at transplant was 1.36 years (0.09-18.25). Donors were: matched unrelated, 73;  43 
1-3 antigen mismatched unrelated, 54; matched sibling, 12; other matched family, 17; 44 
haploidentical, 4. Stem cell source was: peripheral blood stem cells (PBSCs), 70; Bone 45 
marrow, 49; Cord Blood, 41. Median follow up was 4.3 years (0.8-9.4). 46 
Overall survival was 83%. There was no veno- occlusive disease. Seventy-four (46%) had 47 
acute GVHD, but only 14(9%) greater than grade II. Four patients were successfully 48 
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retransplanted for graft loss or poor immune reconstitution. One further patient who 49 
rejected the graft, died.       50 
There was no association between T cell chimerism > 95% and stem cell source, but a 51 
significant association with myeloid chimerism > 95% and use of PBSC without an increased 52 
risk of significant GVHD compared to other sources. All 11 patients  with severe combined 53 
immunodeficiency diagnosed at birth are alive with up to 8.7 years follow up. 54 
Long-term studies are required to determine late gonadotoxic effects and pharmacokinetic 55 
studies are needed to identify whether specific targeting is advantageous. The combination 56 
of treosulfan, fludarabine and alemtuzumab gives excellent results in HSCT for PID. 57 
 58 
Key messages 59 
 Excellent outcome in children undergoing HSCT following treosulfan, fludarabine 60 
and alemtuzumab for Primary Immunodeficiency. 61 
 Better myeloid chimerism achieved using peripheral blood stem cells compared to 62 
bone marrow or cord blood without an increased risk of significant graft versus host 63 
disease. 64 
Capsule summary 65 
We report the largest series to date of children with PID undergoing HSCT following 66 
homogeneous conditioning with treosulfan and fludarabine. Probability of 2 year survival 67 
was 88.3%. Use of PBSC led to better myeloid chimerism. 68 
Key words  69 
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Primary Immunodeficiency; Haematopoietic stem cell transplantation; Treosulfan; 70 
Fludarabine; Chimerism 71 
Abbreviations 72 
HSCT Haematopoietic stem cell transplantation, PID Primary Immunodeficiency, aGVHD 73 
Acute graft versus host disease, cGVHD Chronic graft versus host disease, HLA Human 74 
leucocyte antigen, BM Bone marrow, PBSC Peripheral blood stem cells, CB Cord blood, MSD 75 
Matched sibling donor, ATG Anti thymocyte globulin, PCR Polymerase chain reaction, EBV 76 
Epstein-Barr virus, CMV Cytomegalovirus, SCID Severe Combined Immune deficiency, MUD 77 
Matched unrelated donor, MMUD Mismatched unrelated donor, MFD Matched family 78 
donor, MMFD Mismatched family donor, OS Overall survival, CGD Chronic granulomatous 79 
disease, RAG Recombinant activating gene, ALL Acute lymphocytic leukaemia, ZAP 70 Zeta 80 
associated protein, HLH Haemophagocytic lymphohistiocytosis, LAD Leukocyte adhesion 81 
deficiency, WAS Wiskott Aldrich syndrome, PK Pharmacokinetic 82 
83 




The use of treosulfan as part of conditioning for haematopoietic stem cell transplant (HSCT) 85 
in paediatric practice is increasing for malignant1-4 and non-malignant disorders5-15.  86 
Treosulfan (L-treitol-1,4-bis-methanesulfonate) is the pro-drug of L-epoxybutane, a water 87 
soluble bi-functional alkylating agent with myeloablative and immunosuppressive 88 
properties16 but with less systemic toxicity compared to standard doses of busulfan17. 89 
The use of reduced toxicity conditioning is preferred for patients with primary immune 90 
deficiency (PID) as there is no malignant disease to eradicate, stable mixed chimerism 91 
achieves cure for most patients and many enter HSCT with chronic infection and end-organ 92 
co-morbidities. Additionally, many patients are infants at the time of transplant and may be 93 
more susceptible to toxicity18.  Less toxic regimens may reduce early and late adverse effects 94 
particularly fertility19, 20. There are several reduced toxicity regimens that have been utilised 95 
by investigators in PID21-23. Initial results suggest that specific conditioning regimens may be 96 
preferable in certain PID diseases with severe co-morbidities24, or with donor type and stem 97 
cell source, or appear to have enhanced toxicity in children under one year of age25.  98 
We previously published results of 70 children with PID who received treosulfan in 99 
combination with either cyclophosphamide (n=30) or fludarabine (n=40) with an overall 100 
survival of 81% (median follow up 19 months) equivalent in those aged less or greater than 101 
one year at time of transplant. Toxicity was low but worse after cyclophosphamide, and T 102 
cell chimerism was significantly better after fludarabine9. The numbers involved in this study 103 
were relatively small and follow-up fairly short. We now report 160 consecutive patients 104 
with prolonged follow-up who have received homogeneous conditioning  with treosulfan 105 
and fludarabine without additional agents such as thiotepa, for a wide variety of PID 106 
diagnoses using different types of donor and stem cell source. 107 
108 
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Methods  109 
Patients 110 
We performed a retrospective study of 160 consecutive patients with PID who underwent 111 
HSCT at the two UK supra-regional referral centres for PID; Great North Children’s Hospital, 112 
Newcastle upon Tyne Hospitals NHS Foundation Trust (n=90) and Great Ormond Street 113 
Hospital NHS Foundation Trust (n=70) between February 2006 and July 2013. Information 114 
was collected regarding patient demographics, diagnosis, donor match and stem cell source, 115 
conditioning regimen, transplant related complications, graft-versus-host-disease (GVHD), 116 
chimerism, immune reconstitution, outcome and length of follow up. Patients were not 117 
randomised to receive a specific conditioning regimen and the choice of conditioning was 118 
made by the treating medical team. Informed consent was taken from all parents according 119 
to the local centre and European Blood and Marrow Transplantation and the Declaration of 120 
Helsinki guidelines.  121 
HLA typing was performed by molecular typing for HLA class I and II loci.  The unrelated 122 
donors were all 7-10/10 HLA matched. Bone marrow (BM n= 49), peripheral blood stem cells 123 
(PBSC n=70) and cord blood (CB n=41) were used as a stem cell source. Peripheral blood was 124 
used for the 4 haploidentical transplants, using the Clinimacs (Miltenyi Biotech Ltd, Surrey, 125 
UK) systems for CD3/CD19 depletion. 126 
Treosulfan was given at a dose of 42g/m² (n=102), 36g/m² (n=54) or 30g/m² (n=4) in divided 127 
doses on 3 consecutive days. The lower dose of 36g/m² was given to infants less than 1 year 128 
of age and 30g/m² to Severe combined immunodeficiency (SCID) patients diagnosed at birth 129 
and transplanted very early. Fludarabine 150mg/m² was given to all in 5 divided doses on 130 
consecutive days. Alemtuzumab 0.3 – 1.0mg/kg total dose was given to all the patients 131 
except those who received a matched sibling donor (MSD) graft (n=6), 1 recipient of 132 
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haploidentical CD3/CD19 depleted PBSCs and 30 recipients of CB, 3 of whom received ATG, 133 
but 27 no serotherapy. This reflects a different approach to the use of cord blood between 134 
the 2 centres 26, 27. GVHD prophylaxis in the majority of patients consisted of cyclosporine 135 
with mycophenolate mofetil which was weaned from day plus 28 in the absence of GVHD. 136 
Patients had weekly polymerase chain reaction (PCR) testing of blood for adenovirus, 137 
Epstein-Barr virus (EBV), and cytomegalovirus (CMV). Acute GVHD (aGVHD) was assessed 138 
using the modified Seattle Glucksberg criteria28. Chronic GVHD (cGVHD) was scored 139 
according to the National Institutes of Health criteria29. 140 
Chimerism 141 
Donor chimerism was measured by labelling blood with anti-CD3, -CD19 or -CD15 micro 142 
beads and cell lines were separated using an autoMACS automated bench-top magnetic 143 
cell sorter (Miltenyi Biotec Ltd, Surrey, UK). Separated cells were assayed using variable 144 
number of tandem repeat (VNTR) or XY fluorescence in situ hybridization analysis for sex 145 
mismatched donor-recipient transplants. 146 
Statistics 147 
Statistical analysis was perfomed using STATA version 15. Descriptive analyses were 148 
performed using frequency, median, mean and range. Data were analysed using Pearson chi 149 
square and Kruskall Wallis tests. Survival outcome was evaluated with Kaplan-Meier 150 
estimates and log-rank test. Censoring of patients was defined at time of death or last follow 151 
up or second procedure for event free survival. Multivariable logistic regression analysis was 152 
performed for evaluation for factors influencing aGVHD and chimerism at last follow up. 153 
 154 
 155 




There were 39 patients with SCID, 11 of whom were diagnosed at birth due to previous 157 
family history, and 121 patients with other forms of combined immunodeficiency, 158 
phagocytic disorders, innate defects and disorders of immune regulation as detailed in table 159 
I. The median age at transplant was 1.36 years (range 0.09-18.25). Seventy-six patients were 160 
transplanted at 12 months of age or less. There was no significant difference in their survival 161 
compared with children transplanted over the age of 12 months (p=0.30). 162 
Patients received HSCT from a 10/10 HLA matched unrelated donor (MUD) (n = 73), HLA 163 
MUD (1 to 3 mismatched unrelated donor MMUD) (n = 54), MSD (n=12), other matched 164 
family donor (MFD)  (n=17) or haploidentical mismatched family donor (MMFD) (n=4) using 165 
treosulfan in combination with fludarabine 150mg/m². 166 
Survival 167 
Median follow up was 4.3 years (0.8-9.4). Overall survival (OS) is shown in figure I. Twenty-168 
seven children died giving an OS of 83%. Only 10 died in the first 100 days (100 day survival 169 
of 94%), probability of 2 year survival was 88.3% (95% CI 82.1-92.5%). 170 
Most deaths were associated with infection and/or GVHD and are detailed in table II. One 171 
patient with CGD died on day +1 from multiorgan failure. He had previous Aspergillus and 172 
mycobacterial infection with severe multisystem inflammation and capillary leak despite 173 
high dose steroids and tumour necrosis factor – alpha inhibitor (infliximab) prior to 174 
transplant.  175 
Event free survival is shown in figure II. An event was defined as death or additional 176 
procedure. Four patients were successfully re-transplanted for graft loss or poor immune 177 
reconstitution. In addition, 1 patient with Autoimmune lymphoproliferative syndrome 178 
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rejected a haploidentical graft associated with CMV reactivation and died before re-179 
transplantation. An additional 5 patients received a boost without conditioning from the 180 
original donor. A further 3 patients received donor lymphocyte infusions. Details are shown 181 
in table IV. 182 
Donor and stem cell source 183 
Survival according to type of donor and stem cell source is shown in table III. 184 
There was no significant difference in survival according to type of donor (p=0.5) or stem cell 185 
source (p=0.23). 186 
There has been an increase in the use of PBSC compared to BM (44% and 30.5% 187 
respectively) compared to our previous published series (17% and 57% respectively)9. The 188 
use of CB has remained the same at 26%. 189 
There was a significant difference in median CD34+ stem cell dose according to stem cell 190 
source (p<0.0001): Median dose in CB was 0.4 x 106/kg (0.05-6.3), BM 5.8 x 106/kg (1.1-19.5) 191 
and PBSC 13.7 x 106/kg (2.0-63.8). 192 
Toxicity 193 
Formal grading using the National Cancer Institute toxicity criteria was not carried out as it 194 
was not standard practice at the time in our centres. Mild skin toxicity was common 195 
including perianal ulceration, pigment changes and occasional peeling. Practice now includes 196 
frequent bathing and the avoidance of barrier creams to the skin on the days that treosulfan 197 
is given. Mucositis was mild. Three children had seizures after completing their 3 doses of 198 
treosulfan: all were already on cyclosporine at the time of seizures and all were under 4 199 
months of age. No veno-occlusive disease (VOD) occurred. 200 




Seventy-four (46%) patients had aGVHD, but only 14(9%) had grade III/IV aGVHD. There 202 
were 6 deaths associated with GVHD and its therapy.  Twenty-four patients had cGVHD. 203 
GVHD according to stem cell source is shown in Figure S1. There was no significant 204 
association between acute or chronic GVHD and stem cell source (p=0.37). Twenty-seven of 205 
41 who received CB stem cells did not receive serotherapy and experienced a particularly 206 
high rate of both aGVHD (22 = 82%, although only 2 (7)% with Grade III/IV) and cGVHD (9 of 207 
27, 33%). There was a significantly higher incidence of cGVHD in MMUD compared to MUD 208 
(p= 0.04) but no significant difference in aGVHD either grade I/II or III/IV between MMUD 209 
and MUD. 210 
Viral reactivation 211 
Fifty-six patients had evidence of 1 or more of CMV,EBV and adenovirus replication (35%) 212 
detected by PCR in blood post transplant. CMV was detected in 30 patients (27 of whom 213 
received treatment with foscarnet, ganciclovir or cidofovir), EBV in 21 (6 received treatment 214 
with rituximab, 1 ofatumumab, 1 EBV CTLs), and adenovirus in 24 children (19 of whom 215 
received treatment with cidofovir). In 4 cases these viral infections contributed to the death 216 
of the child. 217 
Chimerism 218 
There was no association between latest T chimerism being > 95% and stem cell source 219 
(p=0.20). However there was a significant overall association with myeloid chimerism 220 
(p=0.005): the odds of having myeloid chimerism > 95% being highest in the PBSC recipients, 221 
followed by cord then bone marrow. (Figure III) 222 
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There was no significant difference between unrelated donor and matched family donor 223 
recipients in donor T (OR 0.9, 95% CI 0.26, 3.21, p=0.90) or myeloid cell chimerism )OR 1.52, 224 
95% CI 0.52, 4.46, p=0.43). 225 
There was no significant difference between those who received 36g/m2 and 42g/m2 226 
treosulfan in terms of achieving T or myeloid chimerism > 95% (p=0.34 and 0.22 227 
repsectively). 228 
Immune reconstitution 229 
Data on lymphocyte reconstitution are shown in supplementary Tables EI to EIII. 230 
There was no association between stem cell source or serotherapy dose and the kinetics of T 231 
lymphocyte reconstitution (at 3 months, 6 months and 12 months post-HSCT). 232 
There were significantly more patients with low age-related B cell numbers at 3 months post 233 
HSCT in the group that received PBSC, but this ceased to be significant by 6 months. Receipt 234 
of high dose Alemtuzumab (1mg/kg) was also associated with delayed B cell reconstitution, 235 
which ceased to be significant by 6 months post-HSCT. 236 
Seven survivors remain on immunoglobulin replacement due to ongoing 237 
immunosuppression in 5, recipient myeloid chimerism with absent B cells in 1 Omenn’s 238 
syndrome patient and poor immune reconstitution despite 100% donor chimerism in a SCID 239 
patient. 240 
Newborn SCIDs 241 
Eleven patients with SCID diagnosed at birth due to positive family history were transplanted 242 
using treosulfan 36g/m2 (n=8) or 30g/m2 (n=3) at less than 5 months of age. All are alive with 243 
15-104 months follow up (median 55 months). All patients are off immunoglobulin 244 
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prophylaxis except 1 who was given rituximab for autoimmune haemolytic anaemia and has 245 
not recovered B cell function. Of 10 patients 6 have 100% and the other 4 have between 246 
74% and 97% donor B cell chimerism.  247 
A further 13 patients who were not diagnosed at birth but presented early were also 248 
transplanted at the age of 4 months or less. Their diagnoses were: SCID (n=6), Omenn’s 249 
syndrome (n=2), ZAP 70 (n=2), HLH (n=1), LAD (n=1), severe immune dysregulation (n=1), 250 
Eight are alive and well with a median follow up of 76 months (40 – 107). The 5 deaths are 251 
detailed in table II. 252 
Wiskott Aldrich Syndrome (WAS) 253 
Twenty patients have been transplanted for WAS all with unrelated donors: 14 MUD and 6 254 
MMUD, 10 PBSC, 7 BM and 3 cords. All are alive and well with a median follow up of 52 255 
months (20 - 102). Eighteen have 100% donor T chimerism, 1 has 82% and another 92%. 256 
Thirteen have > 95% donor myeloid chimerism -  the other 7 patients have between 12 and 257 
92% donor myeloid chimerism. All have normal platelet counts, the patient with 12% 258 
myeloid chimerism having had a splenectomy post HSCT. 259 
Chronic Granulomatous Disease 260 
Seventeen patients have been transplanted for CGD: 1 MSD, 12 MUD, 4 MMUD, 13 PBSC 261 
and 4 BM. Six had fungal disease prior to transplant, 9 had colitis and 4 were second 262 
transplants. Two patients died: one on day + 1 post transplant with multiorgan failure and 263 
the other from grade III GVHD 23 months post transplant. Fifteen are alive and well with a 264 
median follow up of 53 months (24 - 66). Ten have >95% donor myeloid and T cell 265 
chimerism, 4 have > 40% T cell and > 70% myeloid cell chimerism and the remaining patient 266 
lost the graft and was successfully re-transplanted.  267 
Page 13 of 38
14 
 
Haemophagocytic Lymphohistiocytosis (HLH) 268 
Sixteen patients have been transplanted for HLH with only 7 survivors (OS 44%). Six received 269 
CB with no serotherapy, 5 of whom died. An additional MSD BM recipient who did not 270 
receive serotherapy also died. Numbers are small but 6 of 9 who did receive serotherapy are 271 
alive (69%), 1 died D-1 from uncontrolled HLH, 1 had secondary graft failure and died of 272 
Aspergillus pneumonia and 1 had cGVHD and ongoing HLH.  273 
Survival curves for SCID, WAS, CGD and HLH are shown in figure IV.  Survival at 2 years post-274 
HSCT for SCID was 94.6% (80.2 – 98.6%), WAS 100%,CGD 93.7% (63.2 – 99.1%) and HLH 275 
















HSCT following conditioning with treosulfan and fludarabine achieved a probability of 2 year 289 
survival of 87.1% in 160 children with PID with a high level of complete or stable mixed 290 
chimerism in the diseased lineage, sufficient to cure disease.  As in our previous published 291 
series there was a high survival rate in children transplanted under 1 year of age in whom 292 
toxicity can be a problem with conventional and other reduced intensity conditioning 293 
regimens24, 25. A 100 day survival of 94% demonstrates the low toxicity of this regimen 294 
making it suitable for patients with PID who often have infection and organ damage prior to 295 
HSCT. In particular in this series we have demonstrated a higher level of myeloid chimerism 296 
in recipients of PBSC compared to CB and BM, without an increased risk of grade III/IV acute 297 
or chronic GVHD. There was no significant difference in survival according to type of donor  298 
or stem cell source although it would be interesting to evaluate this on a larger number of 299 
patients. 300 
With the advent of newborn screening for SCID and knowing that the outcome of HSCT is 301 
better for those transplanted before the acquisition of infection and organ damage30, it is 302 
important to delineate the best treatment options for such infants31. Good long-term 303 
immune reconstitution requires at least some donor myeloid chimerism, which is much 304 
more reliably achieved when pre-HSCT conditioning is given.32, 33 This report provides 305 
evidence of the safety of using treosulfan in very young infants. Eleven SCID patients 306 
diagnosed at birth due to previous family history and transplanted aged 4 months or under 307 
are alive, 10 with good immune reconstitution. 308 
The outcome for patients with HLH was poor in contrast to Lehmberg’s report of 19 patients 309 
with HLH following HSCT with treosulfan, fludarabine, alemtuzumab, with or without 310 
thiotepa, who achieved 100% survival. Of note in Lehmberg’s report all patients including 311 
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MSD recipients were given alemtuzumab which is likely important due to the 312 
hyperinflammatory nature of the disease8. In particular in our series the combination of cord 313 
blood without serotherapy had a poor outcome and we strongly recommend the inclusion of 314 
serotherapy in future for all patients with HLH. Patients with HLH are unusual in terms of 315 
those with PID in that they receive etoposide to attain remission before HSCT, and survival is 316 
dictated not only by co-morbidities leading to transplant related mortality, but also by 317 
failure to attain complete remission at time of HSCT. 318 
Whilst good results in terms of survival have been achieved using reduced intensity 319 
regimens such as the combination of fludarabine and melphalan, secure engraftment can be 320 
an issue particularly in PID disorders where high levels of donor myeloid chimerism are 321 
required to achieve cure22, 24, 34. In this study we show that the use of PBSCs is associated 322 
with significantly higher myeloid chimerism without any increase in severe GVHD. The 323 
relatively high incidence of grade I/II GVHD may reflect the low threshold for making a 324 
clinical diagnosis of skin GVHD without biopsy, which in other centres may have been 325 
labelled as an engraftment rash. Further work is required to determine optimal timing and 326 
dosing of serotherapy to minimise the risks of GvHD and viral reactivation35. Whilst there 327 
was no significant difference in the incidence of acute GVHD between MUD and MMUD 328 
donors there was a significantly greater risk of chronic GVHD with MMUD. Newer techniques 329 
of T cell depletion such as CD3+TCR alpha/beta together with CD19+ depletion are enabling 330 
a wider spectrum of non SCID PID patients to receive successful haploidentical grafts and will 331 
lead to fewer MMUD being used36-39. 332 
Previously, excellent results have been achieved using a low dose targeted busulfan regimen 333 
in combination with fludarabine40. Prospective studies are needed to compare this to 334 
treosulfan and fludarabine. Data on the longterm effects of treosulfan on fertility are lacking 335 
and need to be compared to other agents19. In addition, further pharmacokinetic studies on 336 
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treosulfan are needed to identify whether specific PK targeting is advantageous, as for 337 
busulfan41-43. Many centres are using additional thiotepa in combination with treosulfan and 338 
fludarabine, but in a recent multicentre study of patients with CGD this did not give superior 339 
results in terms of overall survival, graft survival or higher myeloid chimerism5, and may 340 
result in additional toxicities. However numbers were small and further studies are 341 
warranted.  342 
This study shows that the combination of treosulfan and fludarabine is suitable for 343 
conditioning a diverse range of PID diseases, regardless of age, and with all types of donor 344 
and stem cell source, providing a uniformly applicable conditioning strategy in PID. One 345 
caveat to this may be children with DNA repair disorders where there are few data44, 45. 346 
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Legends for tables and figures 526 
 527 
Figure I Overall survival 528 
 529 
Figure II Event free survival. 530 
 An event was death or additional procedure 531 
Figure III   532 
T and myeloid cell chimerism according to stem cell source. All patients who survived more 533 
than 1 year post HSCT were included. Four patients were excluded for whom there was no 534 
split cell lineage chimerism available. 535 
Figure IV Overall survival by diagnosis 536 
Survival at 2 years post-HSCT: SCID = 94.6% (80.2 – 98.6%), WAS = 100%, CGD = 93.7% (63.2 537 
– 99.1%) and HLH = 62.5% (34.8 – 81.0%)(Log rank test, p = 0.0001). 538 
 539 
Tables 540 
Table I. Patient diagnoses 541 































































Abbreviations: SCID Severe Combined Immunodeficiency, WAS Wiskott Aldrich syndrome, 542 
CGD Chronic granulomatous disease, HLH Haemophagocytic lymphohistiocytosis, SID Severe 543 
Immune dysregulation, CID Combined immunodeficiency, MHC II Major Histocompatibility 544 
Class II deficiency, LAD  Leukocyte adhesion deficiency, CHH Cartilage hair hypoplasia , IPEX 545 
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, CD40L 546 
CD40Ligand deficienc, DOCK 8 Dedicator of cytokinesis 8 deficiency, NKT Natural Killer T cell 547 
deficiency, ZAP 70 Zeta-chain-associated protein kinase 70 deficiency, PI3K 548 
Phosphatidylinositide 3-kinase deficiency, XLP-like X Lymphoproliferative-like syndrome, 549 
XIAP X-linked inhibitor of apoptosis deficiency, ALPS Autoimmune lymphoproliferative 550 
syndrome, CTLA 4 Cytotoxic T lymphocyte antigen 4 deficiency, IRF 8 Interferon regulatory 551 
factor 8 deficiency, FADD Fas-associated death domain protein  deficiency, ITK IL-2-inducible 552 
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T-cell kinase deficiency, NEMO NF-kappa-B essential modulator deficiency, JIA Juvenile 553 







Table II. Deaths 561 
Diagnosis Donor Time post HSCT Cause 
HLH MUD BM Day-2 HLH, toxicity 
CGD  MSD BM Day+1 Severe inflammation, 
toxicity 








MMUD cord 1 month Infection 
(Pseudomonas)  
HLH MUD cord Day+34 Pulmonary 
haemorrhage 
HLH MMUD cord 1.4 months Infection 
(Parainfluenza 3)               
HLH MMUD cord 2 months Infection 
CID MMUD cord 2 months Multiorgan failure 
Omenn’s MUD cord 2.5 months GVHD grade IV  
CID MUD PBSC 5 months GVHD grade IV 
Severe Immune 
dysregulation 
MUD PBSC 5 months Infection (adenovirus) 
 HLH  MUD PBSC 5 months Infection (Aspergillus) 





ALPS MMFD PBSC 6 months Infection (CMV)  
Graft failure 
 
CID MMUD BM 6 months CD20 Neg PTLD, EBV 
HLH MFD BM 8 months GVHD 
Autoimmune 
enteropathy 
MSD BM 10 months Infection (adenovirus) 
Respiratory failure 
HLH MMUD cord 10 months GVHD 
Infection (RSV) 
IPEX MMUD PBSC 11 months Respiratory failure  
Omenn’s MUD BM 11 months GVHD 
Cerebral infarcts  
CGD MUD PBSC 23 months Infection (influenza) 
GVHD  
XIAP MUD PBSC 24 months Infection (JC virus 
Leukoencephalopathy) 
CγC SCID Thymectomy 
due to cardiac surgery 
MFD BM 24 months Respiratory failure 
post DLI  
 
Omenn’s RAG 1 
 
MSD BM 25 months Pneumonitis, Chronic 
lung disease  
RAG SCID MSD BM 33 months Infection whilst being 
treated for Ph+ pre B 
cell ALL (absent donor 
myeloid and B cell 
chimerism) 
HLH MSD BM 36 months MDS/AML 
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SCID MMUD cord 48 months Infection 
 
 562 
Abbreviations: HSCT Haematopoietic stem cell transplantation, HLH Haemophagocytic 563 
lymphohistiocytosis, CGD Chronic granulomatous disease, SCID Severe Combined 564 
Immunodeficiency, CID Combined immunodeficiency, ALPS Autoimmune 565 
lymphoproliferative syndrome, IPEX Immune dysregulation, polyendocrinopathy, 566 
enteropathy, X-linked syndrome, XIAP X-linked inhibitor of apoptosis deficiency, CγC 567 
Common gamma chain, RAG Recombinatin activating gene, BM Bone marrow, PBSC 568 
Peripheral blood stem cells, MUD Matched unrelated donor, MSD Matched sibling donor, 569 
MMUD Mismatched unrelated donor, MMFD Mismatched family donor, GVHD Graft versus 570 
host disease, CMV Cytomegalovirus, EBV Epstein Barr virus, PTLD Post transplant 571 
lymphopoliferative disease, RSV Respiratory syncytial virus, JC John Cunningham, DLI Donor 572 
lymphocyte infusion, Ph Philadelphia, ALL Acute lymphocytic leukaemia, MDS 573 


































Table III. Survival according to donor type and stem cell source 605 
There was no significant difference in survival according to type of donor (p=0.50) or stem 606 
cell source (p=0.23). 607 




PBSC BM Cord Total Survival 
MUD 44 15 14 73 64 
(88.6%) 








0 29 22 
(75.9%) 
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Abbreviations: PBSC Peripheral blood stem cells, BM Bone marrow, MUD Matched unrelated 610 
donor, MSD Matched sibling donor, MMUD Mismatched unrelated donor, MFD Matched 611 











Table IV   Second procedures 623 
Diagnosis 1st 
HSCT 












10m MUD PBSC 
Bu/flu/alem 





Dropped to 0% 
myeloid 
chimerism 
DLI for slipping 
chimerism - no 
effect, then 19m 
MUD PBSC 
Bu/flu/alem 







12m MUD PBSC 
Flu/mel/alem 





16m MMUD PBSC 
Flu/mel/alem 








(Aspergillus) 5m post 1st 
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boost 4m HSCT 
FADD MFD 
PBSC 

























Died infection (influenza) 









Died Infection (JC 
leukoencephalopathy) 2 







DLI 1 year post Died respiratory failure 








DLI 5m post Died infection 
(adenovirus)    Respiratory 








DLI 33m post Liver acute GVHD grade III 
post DLI, resolved. Alive 
and well but ongoing poor 
immune reconstitution 
 624 
Abbreviations: CGD Chronic granulomatous disease, ADA Adenosine deaminase, CHH 625 
Cartilage hair hypoplasia, HLH Haemophagocytic lymphohistiocytosis, FADD Fas-associated 626 
death domain protein  deficiency, XIAP X-linked inhibitor of apoptosis deficiency, PBSC 627 
Peripheral blood stem cells, BM Bone marrow, MUD Matched unrelated donor, MSD 628 
Matched sibling donor, MMUD Mismatched unrelated donor, MFD Matched family donor, 629 
DLI Donor lymphocyte infusion, m months, GVHD Graft versus host disease, Bu Busulfan, flu 630 
fludarabine, mel melphalan, alem alemtuzumab, 631 
 632 
 633 
Supplementary tables 634 
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Table EI Immune reconstitution T cells according to stem cell source 635 
There was no association between the kinetics of T cell reconstitution and different stem cell 636 
sources at 3 months, 6 months and 12 months post-HSCT. 637 
Table E2 Immune reconstitution B cells according to stem cell source 638 
There were significantly more patients with low B cells at 3 months post HSCT in the group 639 
that received PBSC. This ceased to be significant by 6 months. 640 
Table E3 Immune reconstitution T cells according to serotherapy 641 
There was no association between the kinetics of T cell reconstitution and different 642 
serotherapy doses at 3 months, 6 months and 12 months post-HSCT. 643 
Table E4 Immune reconstitution B cells according to serotherapy 644 
There were significantly more patients with low B cells at 3 months post HSCT in the group 645 
that received Alemtuzumab 1mg/kg. This ceased to be significant by 6 months. 646 
Supplementary Figure S1 647 
Graft versus host disease according to stem cell source 648 















Figure I 661 
 662 
At 2 years post-HSCT = 88.3% (95% CI 82.1 – 92.5%) 663 
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Figure II 668 
 An event was death or additional procedure 669 
 670 
 671 
At 2 years post-HSCT = 88.1% (95% CI 81.8 – 92.3%) 672 
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Figure III 678 
 679 
 680 
Abbreviations: PBSC peripheral blood stem cells, BM bone marrow, CB cord blood, T T 681 
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Figure 3.jpg 704 
Page 38 of 38
